Jayex Australia

Jayex are Leaders in Healthcare Self-Service Solutions, Patient Flow and Digital Signage. Jayex is a pioneer in patient flow technology with an extensive and continuous R&D program. Our acclaimed ITK accredited software platform "Enlighten E4"​ is quietly heralding the self-service revolution in Healthcare - reducing labour intensive and paper based processes to deliver dramatic cost savings, accuracy and efficiency. Over 6,500 live systems in surgeries, clinics and hospitals.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

OPTOMED SIGNS AN INDUSTRIAL PARTNERSHIP WITH A FRENCH AI COMPANY OPHTAI

Optomed Oyj | March 21, 2022

news image

Optomed and a French artificial intelligence company OphtAI have signed a commercial collaboration agreement, where both parties sell OphtAI artificial intelligence for screening of most common eye diseases together with Optomed Aurora handheld cameras as a complete solution for eye screening. The agreement is focusing mostly on European countries and Canada, where OphtAI has a strong presence. OphtAI offers artificial intelligence for detection of diabetic retinopathy, glaucoma a...

Read More

PHARMA TECH

ASTRAZENECA, DAIICHI SANKYO PUSH ENHERTU CLOSER TO THE BLOCKBUSTER FRONTIER WITH STOMACH CANCER

Daiichi | January 20, 2021

news image

Daiichi Sankyo and partner AstraZeneca have taken their HER2-targeted cancer drug Enhertu another step toward blockbusterland. The FDA cleared Enhertu for HER2-positive gastric or gastroesophageal junction cancer patients who previously received Roche’s standard-of-care Herceptin, the companies said Monday. An antibody-drug conjugate, Enhertu is the first HER2-directed therapy approved in gastric cancer in a decade, the companies said. And it earned the green ...

Read More

PHARMACY MARKET

VIRPAX ANNOUNCES MMS019 MANUFACTURING AND SUPPLY AGREEMENT

Virpax Pharmaceuticals | August 27, 2021

news image

Virpax® Pharmaceuticals, Inc., a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement with Seqens provides for both the supply material for...

Read More

BUSINESS INSIGHTS

SINORDA BIOMEDICINE AND PORTON ADVANCED TO FAST-TRACK THE DEVELOPMENT OF CELL THERAPIES FOR SOLID TUMORS

Porton Advanced | April 25, 2022

news image

Suzhou Porton Advanced Solutions Ltd. and Guizhou Sinorda Biomedicine Co. Ltd. announced a long-term strategic relationship in cell and gene therapy research and development and platform development. Porton Advanced provides plasmids, cell therapy, gene therapy, oncolytic virus, mRNA treatment, and bacterial therapy as part of an end-to-end gene and cell therapy CDMO service platform. Sinorda Biomedicine focuses on the R&D of revolutionary drugs for digestive tract disorders, ...

Read More
news image

BUSINESS INSIGHTS

OPTOMED SIGNS AN INDUSTRIAL PARTNERSHIP WITH A FRENCH AI COMPANY OPHTAI

Optomed Oyj | March 21, 2022

Optomed and a French artificial intelligence company OphtAI have signed a commercial collaboration agreement, where both parties sell OphtAI artificial intelligence for screening of most common eye diseases together with Optomed Aurora handheld cameras as a complete solution for eye screening. The agreement is focusing mostly on European countries and Canada, where OphtAI has a strong presence. OphtAI offers artificial intelligence for detection of diabetic retinopathy, glaucoma a...

Read More
news image

PHARMA TECH

ASTRAZENECA, DAIICHI SANKYO PUSH ENHERTU CLOSER TO THE BLOCKBUSTER FRONTIER WITH STOMACH CANCER

Daiichi | January 20, 2021

Daiichi Sankyo and partner AstraZeneca have taken their HER2-targeted cancer drug Enhertu another step toward blockbusterland. The FDA cleared Enhertu for HER2-positive gastric or gastroesophageal junction cancer patients who previously received Roche’s standard-of-care Herceptin, the companies said Monday. An antibody-drug conjugate, Enhertu is the first HER2-directed therapy approved in gastric cancer in a decade, the companies said. And it earned the green ...

Read More
news image

PHARMACY MARKET

VIRPAX ANNOUNCES MMS019 MANUFACTURING AND SUPPLY AGREEMENT

Virpax Pharmaceuticals | August 27, 2021

Virpax® Pharmaceuticals, Inc., a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement with Seqens provides for both the supply material for...

Read More
news image

BUSINESS INSIGHTS

SINORDA BIOMEDICINE AND PORTON ADVANCED TO FAST-TRACK THE DEVELOPMENT OF CELL THERAPIES FOR SOLID TUMORS

Porton Advanced | April 25, 2022

Suzhou Porton Advanced Solutions Ltd. and Guizhou Sinorda Biomedicine Co. Ltd. announced a long-term strategic relationship in cell and gene therapy research and development and platform development. Porton Advanced provides plasmids, cell therapy, gene therapy, oncolytic virus, mRNA treatment, and bacterial therapy as part of an end-to-end gene and cell therapy CDMO service platform. Sinorda Biomedicine focuses on the R&D of revolutionary drugs for digestive tract disorders, ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us